TW326045B - N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation. - Google Patents

N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation.

Info

Publication number
TW326045B
TW326045B TW083101092A TW83101092A TW326045B TW 326045 B TW326045 B TW 326045B TW 083101092 A TW083101092 A TW 083101092A TW 83101092 A TW83101092 A TW 83101092A TW 326045 B TW326045 B TW 326045B
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
formula
pharmaceutically acceptable
inhibition
Prior art date
Application number
TW083101092A
Other languages
English (en)
Inventor
Howard Ingall Anthony
Alan Cage Peter
David Kindon Nicholas
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939302636A external-priority patent/GB9302636D0/en
Priority claimed from GB939325712A external-priority patent/GB9325712D0/en
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Application granted granted Critical
Publication of TW326045B publication Critical patent/TW326045B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW083101092A 1993-02-10 1994-02-08 N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation. TW326045B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939302636A GB9302636D0 (en) 1993-02-10 1993-02-10 Compounds
GB939325712A GB9325712D0 (en) 1993-12-16 1993-12-16 Compounds
PCT/GB1994/000237 WO1994018216A1 (en) 1993-02-10 1994-02-08 N-alkyl-2-substituted atp analogues

Publications (1)

Publication Number Publication Date
TW326045B true TW326045B (en) 1998-02-01

Family

ID=26302434

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083101092A TW326045B (en) 1993-02-10 1994-02-08 N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation.

Country Status (26)

Country Link
US (2) US5721219A (zh)
EP (1) EP0683789B1 (zh)
JP (1) JP3083156B2 (zh)
KR (1) KR100315612B1 (zh)
CN (1) CN1042430C (zh)
AT (1) ATE159950T1 (zh)
AU (1) AU679721B2 (zh)
CA (1) CA2155673C (zh)
CZ (1) CZ286050B6 (zh)
DE (1) DE69406649T2 (zh)
DK (1) DK0683789T3 (zh)
ES (1) ES2108425T3 (zh)
FI (1) FI110687B (zh)
GR (1) GR3025995T3 (zh)
HK (1) HK1002936A1 (zh)
HU (1) HU221501B (zh)
IL (1) IL108602A (zh)
NO (1) NO305209B1 (zh)
NZ (1) NZ261159A (zh)
PL (1) PL175623B1 (zh)
RU (1) RU2136693C1 (zh)
SG (1) SG47943A1 (zh)
SK (1) SK281309B6 (zh)
TW (1) TW326045B (zh)
UA (1) UA54366C2 (zh)
WO (1) WO1994018216A1 (zh)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW326045B (en) * 1993-02-10 1998-02-01 Astra Pharma Prod N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation.
WO1998018430A2 (en) * 1996-10-30 1998-05-07 The University Of North Carolina At Chapel Hill P2y receptor antagonists
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
AU2003257524B2 (en) * 1997-07-11 2006-04-06 Astrazeneca Ab New formulation
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6303774B1 (en) * 1999-08-20 2001-10-16 Sri International Nucleoside pyrophosphate and triphosphate analogs and related compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1485395A4 (en) * 2002-02-28 2011-04-13 Biota Scient Management NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
RU2005104432A (ru) * 2002-07-18 2005-08-10 Санкио Компани, Лимитед (Jp) Лекарственная композиция для лечения артериосклероза
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
AU2003284594B2 (en) 2002-11-21 2009-01-15 Kowa Co., Ltd Peritoneal dialysis method
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
AU2010319612B2 (en) * 2009-11-11 2016-01-14 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
EP2669292B1 (en) * 2011-01-26 2017-03-29 Beijing KBD Pharmaceuticals Co., Ltd. Ribofuranosyl purine compounds for treating diseases associated with platelet aggregation
BR112013020377B1 (pt) * 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
CA2843885C (en) 2011-08-01 2020-03-10 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
CN115120606A (zh) 2013-03-09 2022-09-30 奇斯药制品公司 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
CN104447928A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛二水化合物
CN104447927A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛一水合物晶体及其制备方法
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105273025B (zh) * 2014-07-22 2019-07-26 上海医药工业研究院 一种制备坎格雷洛的中间体及其制备方法和应用
PE20221170A1 (es) 2015-01-14 2022-07-25 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN109232694A (zh) * 2015-11-06 2019-01-18 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
CN107973798B (zh) * 2016-10-25 2020-04-24 上海医药工业研究院 2-[(3,3,3-三氟丙基)硫代]-6-氨基-9h-嘌呤及制法
CN107973832B (zh) * 2016-10-25 2021-11-12 上海医药工业研究院 6-n-[2-(甲硫基)乙基]-2-[(3，3，3-三氟丙基)硫代]腺苷的制法
CN106674322B (zh) * 2016-12-07 2019-04-16 上海博志研新药物技术有限公司 一种坎格雷洛中间体的纯化方法
WO2018185715A1 (en) * 2017-04-06 2018-10-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of n6-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene) bisphosphonic acid and its pharmaceutically acceptable salts
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
ES2905104T3 (es) * 2017-11-10 2022-04-07 Olon Spa Método eficiente para la preparación de Cangrelor
CN109912674A (zh) * 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US20190241606A1 (en) * 2018-02-05 2019-08-08 Scinopharm Taiwan, Ltd. Process for preparation of cangrelor tetrasodium and intermediate therefor
CN108033983B (zh) * 2018-02-09 2021-06-08 盐城锦明药业有限公司 一种2‐(3,3,3‐三氟丙基)硫代腺苷的合成方法
EP4289435A1 (en) 2022-06-07 2023-12-13 Université de Liège N-alkyl-2-substituted atp analogues for use as antibacterial agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
WO1990011080A1 (fr) * 1989-03-24 1990-10-04 Daiichi Pharmaceutical Co., Ltd. Medicament ameliorant les fonctions cerebrales
GB9107236D0 (en) 1991-04-06 1991-05-22 Fisons Plc Compounds
ATE127808T1 (de) * 1991-04-06 1995-09-15 Fisons Plc Atp-analogen.
TW326045B (en) * 1993-02-10 1998-02-01 Astra Pharma Prod N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation.

Also Published As

Publication number Publication date
AU679721B2 (en) 1997-07-10
NZ261159A (en) 1997-06-24
NO953126D0 (no) 1995-08-09
DE69406649D1 (de) 1997-12-11
EP0683789A1 (en) 1995-11-29
NO953126L (no) 1995-09-28
SG47943A1 (en) 1998-04-17
JP3083156B2 (ja) 2000-09-04
US5955447A (en) 1999-09-21
IL108602A (en) 1999-12-22
CZ203295A3 (en) 1995-12-13
UA54366C2 (uk) 2003-03-17
CZ286050B6 (cs) 1999-12-15
NO305209B1 (no) 1999-04-19
JPH08506335A (ja) 1996-07-09
US5721219A (en) 1998-02-24
IL108602A0 (en) 1994-05-30
CA2155673A1 (en) 1994-08-18
CN1042430C (zh) 1999-03-10
SK99495A3 (en) 1996-02-07
CN1119869A (zh) 1996-04-03
FI953794A0 (fi) 1995-08-10
EP0683789B1 (en) 1997-11-05
FI110687B (fi) 2003-03-14
RU2136693C1 (ru) 1999-09-10
CA2155673C (en) 2004-08-17
SK281309B6 (sk) 2001-02-12
DE69406649T2 (de) 1998-03-05
KR100315612B1 (ko) 2002-06-20
FI953794A (fi) 1995-08-10
PL310160A1 (en) 1995-11-27
GR3025995T3 (en) 1998-04-30
AU5977094A (en) 1994-08-29
PL175623B1 (pl) 1999-01-29
HK1002936A1 (en) 1998-09-25
HU221501B (en) 2002-10-28
ATE159950T1 (de) 1997-11-15
HUT72464A (en) 1996-04-29
ES2108425T3 (es) 1997-12-16
WO1994018216A1 (en) 1994-08-18
DK0683789T3 (da) 1998-02-09

Similar Documents

Publication Publication Date Title
TW326045B (en) N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation.
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
DK0574545T3 (da) Phenylamidinderivater som blodpladeaggregationsinhibitorer
DK0665844T3 (da) Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans P
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
ZA926049B (en) New 3,5 di-tert.-Butyl-4-hydroxyphenyl derivatives processes for the preparation thereof and pharmaceutical compositions containg them.
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
TW268948B (zh)
CO5080791A1 (es) Derivados de la piperidina que tienen efectos sobre sistemas con serotonina
MY118004A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
ES8504653A1 (es) Un procedimiento para preparar nuevos derivados de eteno
ES8707970A1 (es) Procedimiento para la obtencion de nuevos derivados de la pristinamicina ii b
TW427993B (en) New cephem compounds
MX9305932A (es) Derivados de piperidina, su preparacion y su aplicacion en terapeutica.
NZ205739A (en) Heterocyclic ethane derivatives and fungicidal compositions
ES8707951A1 (es) Derivados de tetrazol
IL103417A0 (en) Bis(phenyl)ethane derivatives,their preparation and pharmaceutical compositions containing them
HUP0303828A2 (hu) CDC25 foszfatáz inhibitorok, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
ATE94050T1 (de) Mittel zur verhinderung von zahnbelagbildung.
SI1572198T1 (sl) Nove farmacevtske spojine z alfa2 receptorsko aktivnostjo
SE7502243L (zh)
TH14595EX (th) เกลือเซฟาโลสพอริน และกรรมวิธีสำหรับเตรียมสารนั้น

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent